Please assess the completion status of the following clinical trial:

Trial Title: Speckle Study: In Arterial, Mixed and Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to enter the study patients must meet the following criteria:~* Age ≥ 18 years~* Intact healthy skin at the site of device application~* Able to understand the Patient Information Sheet~* Willing and able to give informed consent~* Willing and able to follow the requirements of the protocol~* Specific inclusion criteria for the subgroups:~Group A: Arterial Leg Ulcer~* Defined as healing/non-healing Group B: Mixed Leg Ulcer (only to be done once Arterial leg ulcers show change in flux)~* ABPI of \<0.8-0.6 Group C: Diabetic Foot Ulcer - neuropathic~* On clinical inspection present as neuropathic Group D: Diabetic Foot Ulcer - neuroischemic~* On clinical inspection present as neuroischemic~Exclusion Criteria:~Patients will not be admitted to the study if they meet any of the following exclusion criteria:~* Significant (not colonialization) Wound infection either acute or chronic??~* History of significant haematological disorders or DVT with the preceding six months~* Pregnant~* Pacemakers or implantable defibrillators~* Use of any other neuro-modulation device~* Current use of TENS in pelvic region, back or legs~* Use of investigational drug or device within the past 4 weeks that may interfere with this study~* Recent surgery that may affect the study (such as abdominopelvic, or lower limb) in the opinion of the investigator.~* Recent trauma to the lower limbs that will prevent stimulation of the leg with geko (non-responders)~* Size of leg incompatible with the geko™ device., i.e prevents device from stimulating the common peroneal nerve~* obesity (BMI \> 35)~* Any medication deemed to be significant by the Investigator~* Specific exclusion criteria for different subgroups:~Group A: Arterial Leg Ulcer - Mixed leg ulcer, diabetic foot ulcer or diabetic foot ulcer with neuroischaemic element.~Group B: Mixed Leg Ulcer~- Arterial leg ulcer, diabetic foot ulcer or diabetic foot ulcer with neuroischaemic element.~Group C: Diabetic Foot Ulcer - Mixed leg ulcer, Arterial leg ulcer, or diabetic foot ulcer with neuroischaemic element.~Group D: Diabetic Foot Ulcer - neuroischemic~- Mixed leg ulcer, Arterial leg ulcer or diabetic foot ulcer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Group A: Arterial Leg Ulcer (Type: ACTIVE_COMPARATOR): Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
- Group B: Mixed Leg Ulcer (Type: ACTIVE_COMPARATOR): only to be done once Arterial leg ulcers show change in flux ABPI of \<0.8-0.6
- Group C: Diabetic Foot Ulcer - neuropathic (Type: ACTIVE_COMPARATOR): On clinical inspection present as neuropathic
- Group D: Diabetic Foot Ulcer - neuroischemic (Type: ACTIVE_COMPARATOR): On clinical inspection present as neuroischemic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues